Chimigen Biopharma Secures Over RMB 100 Million in First Close of Pre-A Financing Led by SDIC Ventures

Investment Circle (ID: pedaily2012) February 24th news: Recently, Chimigen Bio (Chengdu) Co., Ltd. (hereinafter referred to as "Chimigen Bio") announced the completion ofPre-A Round Financing Exceeding RMB 100 MillionFirst Pass. This round of financing was led bySDIC Venture CapitalLeading Investment,CAS StarFollow-on Investment. This round of financing will be used to accelerate the global clinical trials of core products SN3001 (a therapeutic vaccine for prostate cancer) and SN2001 (an immunotherapy vaccine for chronic hepatitis B), as well as the continuous development of therapeutic cancer vaccine products based on the SynNeogen® core technology platform.

Chimigen Bio is a biotechnology company focused on the development of innovative immunotherapies in the two major disease areas of cancer and viral infections. Relying on the world's first SynNeogen® immunotherapy platform technology, it achieves a novel immunotherapy for "cold tumor transformation" and functional cure through the development of DC cell functions. The company has successively won honors such as Sichuan Province's Specialized, Fine, Distinctive, and Innovative Small and Medium-sized Enterprise, and the Excellence Award in the Disruptive Technology Innovation and Entrepreneurship Competition (Future Health Field). It will adhere to the R&D attitude of "innovation, breakthrough, and truth-seeking" to bring more and better treatment options to patients worldwide.

SDIC Venture Capital stated:The dual explosion of regulatory benefits and clinical demand for therapeutic cancer vaccines has positioned breakthroughs in cold tumor immunotherapy as the industry's pinnacle. Chimigen Bio's SynNeogen® platform addresses the fundamental challenge of 'cold tumor immune activation,' offering potential solutions to two major development hurdles in therapeutic vaccines: antigen delivery and immune tolerance. Guided by the mission of "serving China's innovation strategy and focusing on the transformation of scientific achievements," as a key player in the field of therapeutic cancer vaccines backed by SDIC Venture Capital, we believe in Chimigen Bio’s disruptive potential in the cancer vaccine space. We are delighted to welcome Chimigen Bio into SDIC Venture Capital's innovation ecosystem, where it will leverage its platform advantages to efficiently integrate industry resources and empower Chimigen Bio's rapid growth.

Dr. Yue Nian Shi, founder of Chimigen Bio, stated:Chimigen Bio Welcomes SDIC Venture Capital and CAS Star as New ShareholdersWe warmly welcome SDIC Venture Capital and CAS Star to become new shareholders of the company. Against the backdrop of the current industry capital winter, the first closing of Chimigen Bio's financing round fully demonstrates the high recognition by the capital market of our platform technology and the clinical value and commercial prospects of our core pipeline. As an innovation-driven enterprise established during the pandemic and growing amidst the capital winter, we focus on cancer and viral infection immunotherapy, striving to build a differentiated product pipeline with global competitiveness. We extend our heartfelt thanks to both new and existing shareholders for their strong support at this critical stage of corporate development. Chimigen Bio will continue to deepen its R&D philosophy of "innovation-led and science-based," accelerate the development of multiple therapeutic vaccine products with internationally leading standards and significant clinical value, achieve clinical translation through breakthrough innovations, and contribute social value to the global health cause.